Anna Maria F.
- Country
- Italy
- Department
- EMATOLOGIA
Research Overview
- Dose-Escalation and Expansion Study of BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein Degrader, in Patients with B-Cell Malignancies
- Evaluation of Adverse Events, Pharmacokinetics, and Disease Activity of Oral ABBV-101 in Adult Patients with Select B-Cell Malignancies
- A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA-25) – Substudy A – Relapsed/Refractory Waldenstrom Macroglobulinemia
Data & Insights
Has run more than one trial at 227 of 411 partner sites.
Specializations
Primary Research Focus
This investigator specializes in treating chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), with particular emphasis on developing innovative treatment approaches for both newly diagnosed and relapsed/refractory cases.
- Novel therapeutic combinations
- Treatment optimization strategies
- Targeted therapy approaches
Specialized Treatment Areas
The investigator focuses on evaluating various therapeutic agents including BTK inhibitors, BCL-2 inhibitors, and monoclonal antibodies in treating B-cell malignancies.
- Marginal zone lymphomas
- Burkitt lymphoma
- Richter transformation
Treatment Innovation
Active involvement in studying fixed-duration therapies and combination treatments for hematologic malignancies, with particular interest in developing personalized treatment approaches.
- Immunotherapy development
- Cell therapy research
- Long-term treatment outcomes
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.